Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

IL-17 mediates resistance to anti-VEGF therapy

Nature Medicine volume 19, pages 1092–1094 (2013)Cite this article

Subjects

Interleukin-17 (IL-17) released in the tumor microenvironment in response to drugs blocking vascular endothelial growth factor (VEGF) triggers stromal-derived inflammatory and VEGF-independent angiogenic programs that induce the drug refractoriness found in cancers resistant to anti-angiogenic therapy (pages 1114–1123).

Angiogenesis, the formation of new blood vessels, is a fundamental physiological process tightly regulated to support changing tissue requirements during development, growth and wound healing1. In pathological situations, including cancer, as the progressing tumor demands blood vessels for nutrition and oxygen supply, angiogenic pathways are induced by tilting the balance toward proangiogenic factors to drive vascular growth1. Angiogenesis is generally accepted as a rate-limiting process during tumor growth, and inhibitors of angiogenesis that target the proangiogenic VEGF and its receptor VEGFR are being used as adjuvant therapies in several cancers, including solid and hematological malignancies2. However, not all patients benefit from anti-angiogenic therapies, and in the majority of those responding to therapy, the disease progresses later on3. The transient nature of the therapeutic response and the short duration of patient survival suggest the tumor angiogenesis cascade is complex.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Stroma-mediated development of anti-VEGF resistance.

Marina Corral Spence

References

  1. Carmeliet, P. & Jain, R.K. Nature 473, 298–307 (2011).

    Article  CAS  Google Scholar 

  2. Ferrara, N. & Kerbel, R.S. Nature 438, 967–974 (2005).

    Article  CAS  Google Scholar 

  3. Kieran, M.W., Kalluri, R. & Cho, Y.J. Cold Spring Harb. Perspect. Med. 2, a006593 (2012).

    Article  Google Scholar 

  4. Leek, R.D., Harris, A.L. & Lewis, C.E. J. Leukoc. Biol. 56, 423–435 (1994).

    Article  CAS  Google Scholar 

  5. Holash, J. et al. Science 284, 1994–1998 (1999).

    Article  CAS  Google Scholar 

  6. Chung, A.S. et al. Nat. Med. 19, 1114–1123 (2013).

    Article  CAS  Google Scholar 

  7. McMillin, D.W., Negri, J.M. & Mitsiades, C.S. Nat. Rev. Drug Discov. 12, 217–228 (2013).

    Article  CAS  Google Scholar 

  8. De Palma, M. & Lewis, C. Cancer Cell 23 Issue 3, 277–286 (2013).

    Article  CAS  Google Scholar 

  9. Du, R. et al. Cancer Cell 13, 206–220 (2008).

    Article  CAS  Google Scholar 

  10. Bergers, G. & Song, S. Neuro Oncol. 7, 452–464 (2005).

    Article  CAS  Google Scholar 

  11. De Palma, M. et al. Cancer Cell 8, 211–226 (2005).

    Article  CAS  Google Scholar 

  12. Gabrilovich, D.I., Ostrand-Rosenberg, S. & Bronte, V. Nat. Rev. Immunol. 12, 253–268 (2012).

    Article  CAS  Google Scholar 

  13. Crawford, Y. et al. Cancer Cell 15, 21–34 (2009).

    Article  CAS  Google Scholar 

  14. Shojaei, F. et al. Nat. Biotechnol. 25, 911–920 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Eleni Maniati and Thorsten Hagemann are at the Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London, UK.,

    Eleni Maniati & Thorsten Hagemann

Authors
  1. Eleni Maniati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thorsten Hagemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thorsten Hagemann.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Maniati, E., Hagemann, T. IL-17 mediates resistance to anti-VEGF therapy. Nat Med 19, 1092–1094 (2013). https://doi.org/10.1038/nm.3333

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.3333

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer